Abstracts Archive - Page 754 of 2425 - ACR Meeting Abstracts

Abstract Number: 1490 • ACR Convergence 2020
Pain Rating Variability and Response to Treatment in Osteoarthritis Clinical Trials
Camila Pinto¹, Joana Barroso² and Thomas Schnitzer³, ¹Department of Physiology, Northwestern University Feinberg School of Medicine, Chicago, IL, ²Department of Physiology, Northwestern University, Feinberg School of Medicine, Chicago, IL, ³Northwestern University Feinberg School of Medicine, Chicago, IL
Background/Purpose: Despite the known high inter- and intra-patient variability in analgesic responses in chronic pain, most interventional pain studies rely on single time point pain…
Abstract Number: 1491 • ACR Convergence 2020
Association of a Leaky Gut but Not Microbial Dysbiosis with Obesity-related OA: A Translational Study
Richard Loeser¹, Liubov Arbeeva¹, Kathryn Kelley², Anthony Fodor³, Shan Sun³, Veronica Ulici⁴, Lara Longobardi², Yang Cui², Susan Sumner², Andrea Azcarate-Peril², Balfour Sartor², Ian Carrol² and Amanda Nelson¹, ¹University of North Carolina at Chapel Hill Thurston Arthritis Research Center, Chapel Hill, NC, ²University of North Carolina, Chapel Hill, NC, ³University of North Carolina-Charlotte, Charlotte, NC, ⁴Brown University, Providence, RI
Background/Purpose: To test the hypothesis that an altered gut microbiota (dysbiosis) plays a causal role in the obese OA phenotype (obesity with both hand and…
Abstract Number: 1492 • ACR Convergence 2020
The Childhood Arthritis and Rheumatology Research Alliance Start Time Optimization of Biologic Therapy in Polyarticular JIA Study: Report of Primary Study Outcomes
Yukiko Kimura¹, George Tomlinson², Laura Schanberg³, Mary Ellen Riordan⁴, Anne Dennos⁵, Vincent Del Gaizo⁶, Katherine Murphy⁷, Pamela F. Weiss⁸, Brian Feldman⁹ and Sarah Ringold¹⁰, ¹Hackensack Meridian School of Medicine, Hackensack, NJ, ²Department of Medicine, University Hospital Network, Toronto, Toronto, ON, Canada, ³Duke University Medical Center, Durham, NC, ⁴Hackensack University Medical Center, Westwood, NJ, ⁵Duke University, Durham, NC, ⁶Childhood Arthritis & Rheumatology Research Alliance (CARRA), Whitehouse Station, NJ, ⁷Lousiana Department of Public Health, New Orleans, LA, ⁸Children's Hospital of Philadelphia, Philadelphia, ⁹The Hospital for Sick Children, Toronto, ON, Canada, ¹⁰Seattle Children's, Seattle, WA
Background/Purpose: There is uncertainty regarding when to start biologic medications for polyarticular juvenile idiopathic arthritis (P-JIA). The Childhood Arthritis and Rheumatology Research Alliance (CARRA) developed…
Abstract Number: 1493 • ACR Convergence 2020
Distinct Patient-level Patterns of Response to Methotrexate in Juvenile Idiopathic Arthritis
Stephanie Shoop-Worrall¹, Kimme Hyrich², Lucy Wedderburn³, Wendy Thomson⁴ and Nophar Geifman⁵, ¹Centre for Health Informatics, Centre for Epidemiology Versus Arthritis, The University of Manchester, Manchester, United Kingdom, ²Centre for Epidemiology Versus Arthritis, Manchester Academic Health Science Centre, The University of Manchester, Manchester, United Kingdom, ³UCL, UCLH, GOS Institute of Child Health, London, United Kingdom, ⁴Centre for Genetics and Genomics Versus Arthritis, Manchester Academic Health Science Centre, The University of Manchester, Manchester, United Kingdom, ⁵Centre for Health Informatics, The University of Manchester, Manchester
Background/Purpose: Treatment response in JIA is often viewed as a binary outcome: response or non-response, usually assessed using composite, multidimensional measures, such as the juvenile…
Abstract Number: 1494 • ACR Convergence 2020
Patient-Reported Adverse Events, Quality of Life and Treatment Adherence in Juvenile Idiopathic Arthritis: Analysis of Two Large International Cohorts
Alessandra Alongi¹, Maria Trachana², Valda Stanevicha³, Laura Marinela Ailioaie⁴, Elena Tsitsami⁵, Angelo Ravelli⁶, Alessandro Consolaro⁶ and Nicolino Ruperto⁷, ¹IRCCS Istituto Giannina Gaslini, Genoa, Italy, ²Aristotle University of Thessaloniki, Thessaloníki, Greece, ³Riga Stradins University, Riga, Latvia, ⁴Alexandru Ioan Cuza University of Iasi, Iasi, Romania, ⁵Aghia Sophia Childrens Hospital, Athens, Greece, ⁶Università degli Studi di Genova, Genoa, Italy, ⁷Istituto Giannina Gaslini, Genova, Italy
Background/Purpose: Juvenile idiopathic arthritis (JIA) patients may experience significant medication-related adverse effects (AEs), which may adversely affect health-related quality of life (HRQOL), daily activities and…
Abstract Number: 1495 • ACR Convergence 2020
Tofacitinib for the Treatment of Patients with Juvenile Idiopathic Arthritis: An Interim Analysis of Data up to 5.5 Years from an Open-label, Long-term Extension Study
Hermine I Brunner¹, Jonathan Akikusa², Eslam Al-Abadi², John Bohnsack³, Alina Lucica Boteanu², Gaelle Chedeville⁴, Ruben Cuttica², Wendy De La Pena⁴, Lawrence Jung⁴, Ozgur Kasapcopur², Katarzyna Kobusinska², Grant Schulert¹, Claudia Neiva², Rafael Rivas-Chacon⁴, Juan Cruz Rizo Rodriguez², Monica Vazquez-Del Mercado², Linda Wagner-Weiner⁴, Jennifer E Weiss¹, Carine Wouters², Ricardo M Suehiro⁵, Holly Posner⁶, Ann Wouters⁶, Keith S Kanik⁷, Zhen Luo⁸, Alberto Martini², Daniel J Lovell¹ and Nicolino Ruperto², ¹PRCSG, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, ²PRINTO, Istituto Giannina Gaslini, Genova, Italy, ³University of Utah and Primary Children's Hospital, Cincinnati, OH, ⁴PRCSG, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁵Pfizer Inc, Collegeville, PA, ⁶Pfizer Inc, New York, NY, ⁷Pfizer Inc, Groton, CT, ⁸Pfizer Inc, Shanghai, China (People's Republic)
Background/Purpose: Tofacitinib is an oral JAK inhibitor that is being investigated for JIA. We report the safety, tolerability, and efficacy of tofacitinib in patients (pts)…
Abstract Number: 1496 • ACR Convergence 2020
Outcomes of an Evidence Based Guideline for the Treatment of Hemophagocytic Lymphohistiocytosis and Macrophage Activation Syndrome
Kacie Hoyt¹, Olha Halyabar², Joseph Han³, Siobhan Case⁴, Margaret Chang¹, Craig Platt⁵, Ezra Cohen¹, Megan Day-Lewis⁵, Fatma Dedeoglu¹, Jonathan Hausmann⁶, Erin Janssen², Pui Lee⁷, Jeffrey Lo¹, Gregory Priebe⁵, Mindy Lo¹, Esra Meidan⁸, Peter Nigrovic⁹, Jordan Roberts¹, Mary Beth Son¹, Robert Sundel², Mark Gorman¹, Barbara Degar¹⁰, Melissa Hazen¹ and Lauren Henderson¹¹, ¹Boston Children's Hospital, Boston, MA, ²Children's Hospital/Boston Medical Center, Boston, MA, ³Mount Sinai School of Medicine, New York, NY, ⁴Brigham and Women's Hospital, Boston, MA, ⁵Boston Children's Hospital, Boston, ⁶Boston Children's Hospital / Beth Israel Deaconess Medical Center, Cambridge, MA, ⁷1.Boston Children's Hospital;2.Brigham and Women's Hospital;3.Harvard Medical School, Newton, MA, ⁸Boston Children's Hospital, Somerville, MA, ⁹Division of Rheumatology, Inflammation and Immunity, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA; Division of Immunology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA, Boston, ¹⁰Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston, ¹¹Boston Children's Hospital, Watertown, MA
Background/Purpose: Rapid identification of HLH/MAS coupled with a multidisciplinary approach to management is essential to improve patient outcomes. We describe our experience with a newly…
Abstract Number: 1497 • ACR Convergence 2020
COVID-19 in Pregnant Patients with Rheumatic Disease: Data from the COVID-19 Global Rheumatology Alliance
Bonnie Bermas¹, Megan Clowse², Milena Gianfrancesco³, Jonathan Hausmann⁴, Pedro M Machado⁵, Emily Sirotich⁶, Helen Robinson⁷, Anja Strangfeld⁸, Jinoos Yazdany⁹ and Philip Robinson¹⁰, ¹UTSouthwestern.edu, Dallas, TX, ²Duke University, Chapel Hill, NC, ³University of California, San Francisco, San Francisco, CA, ⁴Boston Children's Hospital / Beth Israel Deaconess Medical Center, Cambridge, MA, ⁵University College London, London, United Kingdom, ⁶McMaster University, Hamilton, ON, Canada, ⁷University of Queensland School of Medicine, HERSTON, Queensland, Australia, ⁸German Rheumatism Research Center, Berlin, Germany, ⁹UCSF, San Francisco, CA, ¹⁰University of Queensland, Herston, Queensland, Australia
Background/Purpose: The impact of COVID-19 on pregnancy in patients with rheumatic disease is unknown. We describe COVID-19 outcomes in pregnant rheumatic disease patients reported to…
Abstract Number: 1498 • ACR Convergence 2020
Pregnancy Outcomes in Patients with Axial Spondyloarthritis – a First Analysis of a European Collaboration of Pregnancy Registries
Yvette Meissner¹, Nathalie Costedoat-Chalumeau², Frauke Foerger³, Doreen Goll⁴, Anna Molto⁵, Rebecca Özdemir⁶, Marianne Wallenius⁷, Anja Strangfeld⁸ and Rebecca Fischer-Betz⁹, ¹Deutsches Rheuma-Forschungszentrum, Berlin, Germany, ²APHP, Université de Paris, Paris, France, ³University Hospital and University of Bern, Bern, Switzerland, Bern, Switzerland, ⁴Patient Research Partner, Berlin, Germany, ⁵Rheumatology Department, Cochin Hospital, Paris, Paris, France, ⁶Patient Research Partner, Duisburg, Germany, ⁷University Hospital and Norwegian University of Science and Technology, Trondheim, Norway, ⁸German Rheumatism Research Center, Berlin, Germany, ⁹Department of Rheumatology and Hiller Research Unit Rheumatology, Heinrich Heine University, Duesseldorf, Germany, Duesseldorf, Germany
Background/Purpose: Axial spondyloarthritis (axSpA) can affect women in their childbearing age. Data on pregnancy in axSpA patients are mainly retrospective and highly heterogeneous [1]. The…
Abstract Number: 1499 • ACR Convergence 2020
The Frequency of Contraception Documentation in Women with Lupus and Rheumatoid Arthritis Within the RISE Registry
Megan Clowse¹, Jing Li², Amanda Eudy³, Mehret Birru Talabi⁴ and Gabriela Schmajuk⁵, ¹Duke University, Chapel Hill, NC, ²University of California, San Francisco, San Francisco, CA, ³Duke University, Durham, NC, ⁴University of Pittsburgh, Pittsburgh, PA, ⁵University of California, San Francisco, Atherton, CA
Background/Purpose: Several of the most commonly prescribed anti-rheumatic medications for women with rheumatic disease are known teratogens, posing a risk for pregnancy loss and birth…
Abstract Number: 1500 • ACR Convergence 2020
Electrocardiographic QT Intervals in Infants Exposed to Hydroxychloroquine Throughout Gestation
Deborah Friedman¹, Mimi Kim², Nathalie Costedoat-Chalumeau³, Robert Clancy⁴, Joshua Copel⁵, Colin Phoon⁶, Bettina Cuneo⁷, Rebecca Cohen⁶, Mala Masson⁶, Benjamin Wainwright⁶, Noel Zahr⁸, Amit Saxena⁴, Peter Izmirly⁹ and Jill Buyon¹⁰, ¹New York Medical College, Valhalla, ²Albert Einstein College of Medicine, Bronx, ³APHP, Université de Paris, Paris, France, ⁴NYU School of Medicine, New York, ⁵Yale School of Medicine, New Haven, ⁶New York University School of Medicine, New York, ⁷University of Colorado School of Medicine, Aurora, ⁸Pitié-Salpêtrière University Hospital, Paris, France, ⁹Department of Medicine, New York University School of Medicine, New York, NY, ¹⁰Department of Medicine, NYU School of Medicine, New York, NY
Background/Purpose: Based on inhibition of viral replication and limited reports on clinical efficacy, hydroxychloroquine (HCQ) was initially considered as a prophylaxis and treatment of COVID-19. …
Abstract Number: 1501 • ACR Convergence 2020
Obstetrical Outcome and Thromboses in a Multicentric Cohort of Antiphospholipid Syndrome (APS) Patients with Severe Preeclampsia: An Analysis of APS Classification Criteria
Maddalena Larosa¹, Nathalie Morel², Meriem Belhocine³, Amelia Ruffatti⁴, Nicolas Martin Silva⁵, Romain Paule⁶, Luc Mouthon⁷, Michel Dreyfus⁸, Jean-Charles Piette⁹, Odile Souchaud-Debouverie¹⁰, Catherine Deneux-Tharaux¹¹, Vassilis Tsatsaris¹², Emmanuelle Pannier Metzger¹³, Gaëlle Guettrot-Imbert¹⁴, Veronique Le Guern¹⁵, Andrea Doria¹⁶ and Nathalie Costedoat-Chalumeau¹⁷, ¹Rheumatology Unit-Department of Medicine-University of Padova, Italy, Padova, Veneto, Italy, ²AP-HP, université René-Descartes Paris V, hôpital Cochin, centre de référence maladies auto-immunes et systémiques rares, pôle médecine, service de médecine interne, Paris, France., Paris, Ile-de-France, France, ³Hôpital Sacré-Coeur de Montréal , Montréal, Montreal, QC, Canada, ⁴Department of Medicine, University of Padova, Padova, Veneto, Italy, ⁵Centre Hospitalier et Universitaire de Caen, Caen, France, ⁶Foch Hospital, Paris, France, ⁷Hopital Cochin - Paris University, Paris, France, ⁸CHU de Caen, Caen, France, ⁹Department of Internal Medicine, Hôpital Pitié-Salpêtrière, Paris, France, Paris, France, ¹⁰CENTRE HOSPITALIER UNIVERSITAIRE LA MILETRIE, poitiers, France, ¹¹INSERM U1153, Obstetrical, Perinatal and Pediatric Epidemiology Research Team, Center for Epidemiology and Statistics Sorbonne Paris Cité , Paris Descartes University , Paris , France, Paris, France, ¹²Maternité Port-Royal,Hôpital Cochin, Paris, France, Paris, France, ¹³Maternité Port-Royal,Hôpital Cochin, Paris, France, ¹⁴Médecine Interne,Hôpital Cochin, paris, France, ¹⁵Médecine Interne,Hôpital Cochin, Paris, France, Paris, France, ¹⁶University of Padua, Padua, Italy, ¹⁷APHP, Université de Paris, Paris, France
Background/Purpose: According to APS classification criteria1, clinical manifestations of antiphospholipid syndrome (APS) consist in thrombotic and obstetric events, including severe preeclampsia (PE). Because little is…
Abstract Number: 1502 • ACR Convergence 2020
Composite of Relevant Endpoints for Sjögren’s Syndrome (CRESS)
Suzanne Arends¹, Liseth de Wolff², Jolien van Nimwegen³, Gwenny Verstappen², Jelle Vehof², Arjan Vissink⁴, Neelanjana Ray⁵, Frans Kroese² and Hendrika Bootsma², ¹University Medical Centre Groningen and Medical centre Leeuwarden, Groningen, Netherlands, ²University Medical Centre Groningen, Groningen, Netherlands, ³University Medical Center Groningen, Groningen, Netherlands, ⁴University Medical Centre Groningen, Leek, Netherlands, ⁵Bristol-Myers Squibb, Lawrenceville
Background/Purpose: Several recent randomized controlled trials that used the validated ESSDAI as primary endpoint failed, partly explained by relatively large response rates in the placebo…
Abstract Number: 1503 • ACR Convergence 2020
Ultra High‐resolution Ultrasound (UHFUS) of Labial Salivary Glands Might Help to Avoid Unnecessary Lip Biopsy in Patients with Sicca Syndrome
Chiara Baldini¹, Francesco Ferro¹, Rossana Izzetti², Saverio Vitali³, Giacomo Aringhieri³, Silvia Fonzetti⁴, Marta Mosca¹, Valentina Donati⁵, Stefano Bombardieri¹ and Davide Caramella³, ¹Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy, ²Department of Surgical Pathology, Medicine, Molecular and Critical Area, University of Pisa, Pisa, Italy, Pisa, ³Diagnostic and Interventional Radiology, Department of Translational Research and of New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy, Pisa, ⁴Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, ⁵Pathology Unit, AOUP, Pisa
Background/Purpose: Major salivary gland ultrasonography (SGUS) has an established role as a first-line imaging tool in the diagnosis of primary Sjögren’s syndrome (pSS). Nowadays, however,…
Abstract Number: 1504 • ACR Convergence 2020
Four Distinct Symptom-Based Clusters Identified from the Sjӧgren’s Foundation Survey
Sara McCoy¹, Christie Bartels², Miguel Woodham¹, Noah Maerz¹, Esen Akpek³, Ian Saldanha⁴, Matthew Makara⁵ and Alan Baer⁶, ¹University of Wisconsin, Madison, ²University of Wisconsin School of Medicine and Public Health, Department of Medicine, Division of Rheumatology, Madison, WI, ³Johns Hopkins University, Baltimore, ⁴Brown University, Providence, ⁵Sjogren's Syndrome Foundation, Reston, ⁶Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Relief of symptoms is a sine qua non for successful drug development in Sjӧgren’s syndrome (SS). However, symptom-based patient experience is understudied, particularly how…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].